Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different β-lactam resistance phenotypes

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 4, 1999, Pages 862-867

  Oliver, Antonio ^a   Pérez Vázquez, María ^a   Martínez Ferrer, Manuel ^a   Baquero, Fernando ^a   De Rafael, Luis ^a   Cantón, Rafael ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM; BETA LACTAMASE; SULTAMICILLIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG POTENCY; ENZYME ACTIVITY; ENZYME SYNTHESIS; ESCHERICHIA COLI; LABORATORY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

EID: 0344958588     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.4.862     Document Type: Article

References (40)

1. Aldridge, K. E., C. V. Sanders, and R. L. Marier. 1986. Variation in the potentiation of β-lactam antibiotic activity by clavulanic acid and sulbactam against multiply antibiotic-resistant bacteria. J. Antimicrob. Chemother. 17: 463-469.
2. Baquero, F., J. Martínez-Beltrán, R. Cantón, and los Restantes Miembros del Grupo MENSURA. 1997. Criterios del Grupo MENSURA para la definición de los puntos críticos de sensibilidad a los antibióticos. Rev. Esp. Quimioter. 10:303-313.
3. Blázquez, J., M.-R. Baquero, R. Cantón, I. Alos, and F. Baquero. 1993. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli. Antimicrob. Agents Chemother. 37:2059-2063.
4. Comité de ĺ Antibiograme de la Société Française de Microbiologie. 1996. Statement 1996. CA-SFM. Zone sizes and MIC breakpoints for non-fastidious organisms. Clin. Microbiol. Infect. 2(Suppl. 1):S46-S49.
5. Foulds, G. 1986. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev. Infect. Dis. 8:S503-S511.
6. Greenwood, D. 1996. Fixed or variable concentrations of beta-lactamase inhibitors in in-vitro tests? J. Antimicrob. Chemother. 38:17-20.
7. Huovinen, S. 1988. Rapid isoelectric focusing of plasmid-mediated β-lactamases with Pharmacia PhastSystem. Antimicrob. Agents Chemother. 32: 1730-1732.
8. Jarlier, V., M. H. Nicolas, G. Fournier, and A. Philippon. 1988. Extended spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev. Infect. Dis. 10:867-878.
9. Liu, P. Y., D. Gur, L.-M. Hall, and D. M. Livermore. 1997. Survey of the prevalence of beta-lactamases amongst 1000 gram-negative bacilli isolated consecutively at the Royal London Hospital. J. Antimicrob. Chemother. 39:1-3.
10. Livermore, D. M. 1993. Determinants of the activity of betalactamase inhibitor combinations. J. Antimicrob. Chemother. 31:9-21.
11. Livermore, D. M. 1995. β-Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8:557-584.
12. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
13. Marre, R., and S. Aleksic. 1990. Beta-lactamase types and beta-lactam resistance of Escherichia coli strains with chromosomally mediated ampicillin resistance. Eur. J. Clin. Microbiol. Infect. Dis. 9:44-46.
14. Martinez, J. L., E. Cercenado, M. Rodríguez-Creixems, M. F. Vicente-Pérez, A. Delgado-Iribarren, and F. Baquero. 1987. Resistance to beta-lactam/clavulanate. Lancet ii:1473.
15. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
16. National Committee for Clinical Laboratory Standards. 1997. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
17. Neu, H. C. 1987. Penicillin-binding proteins and beta-lactamases: their effects on the use of cephalosporins and other new beta-lactams. Curr. Clin. Top. Infect. Dis. 8:37-61.
18. Normark, S., S. Lindquist, and F. Lindberg. 1986. Chromosomal beta-lactam resistance in enterobacteria. Scand. J. Infect. Dis. 49:38-45.
19. Oliver, A., M. Pérez-Vázquez, M. Martínez-Ferrer, F. Baquero, S. Valdezate, and R. Cantón, Ampicillin-sulbactam and co-amoxiclav susceptibility testing on Escherichia coli: fixed ratio or fixed concentration?, abstr. D-46, p. 142. In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
20. O'Shaughnessy, E. M., G. A. Fahle, and F. G. Witebsky. 1997. Correlation of in vitro susceptibility results for amoxicillin-clavulanate and ampicillin-sulbactam tested against Escherichia coli. J. Clin. Microbiol. 35:1902-1903.
21. Payne, D. J., R. Cramp, D. J. Winstanley, and D. J. C. Knowles. 1994. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important β-lactamases. Antimicrob. Agents Chemother. 38:767-772.
22. Pfaller, M. A., L. Barry, P. C. Fuchs, E. H. Gerlach, D. J. Hardy, and J. C. McLaughlin. 1993. Comparison of fixed concentration and fixed ratio options for dilution susceptibility testing of gram-negative bacilli to ampicillin and ampicillin/sulbactam. Eur. J. Clin. Microbiol. Infect. Dis. 12:356-362.
23. Piddock, L. J., R. N. Walters, Y. F. Jin, H. L. Turner, D. M. Gascoyne-Binzi, and P. M. Hawkey. 1997. Prevalence and mechanism of resistance to 'third-generation' cephalosporins in clinically relevant isolates of Enterobacteriaceae from 43 hospitals in the UK, 1990-1991. J. Antimicrob. Chemother. 39:177-187.
24. Reguera, J. A., F. Baquero, J. C. Pérez-Díaz, and J. L. Martínez. 1991. Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli. J. Antimicrob. Chemother. 27:569-575.
25. Roy, C., C. Segura, A. Torrellas, R. Reig, D. Teruel, and M. Hermida. 1989. Activity of amoxycillin/clavulanate against beta-lactamase-producing Escherichia coli and Klebsiella spp. J. Antimicrob. Chemother. 24:41-47.
26. Roy, C., C. Segura, M. Tirado, R. Reig, M. Hermida, D. Teruel, and A. Foz. 1985. Frequency of plasmid-determined beta-lactamases in 680 consecutively isolated strains of Enterobacteriaceae. Eur. J. Clin. Microbiol. 4:146-147.
27. Sanders, C. C., and W. E. Sanders. 1992. Beta-lactam resistance in gram-negative bacteria: global trends and clinical impact. Clin. Infect. Dis. 15:824-839.
28. Sawai, T., A. Yamaguchi, and R. Hiruma. 1988. Effect of interaction between outer membrane permeability and beta-lactamase production on resistance to beta-lactam agents in gram-negative bacteria. Rev. Infect. Dis. 10:761-764.
29. Schumacher, H., U. Skibsted, R. Skov, and J. Scheibel. 1996. Cefuroxime resistance in Escherichia coli. Resistance mechanisms and prevalence APMIS 104:531-538.
30. Seetulsingh, P. S., L. M. Hall, and D. M. Livermore. 1991. Activity of clavulanate combinations against TEM-1 beta-lactamase-producing Escherichia coli isolates obtained in 1982 and 1989. J. Antimicrob. Chemother. 27:749-759.
31. Stapleton, P., P.-J. Wu, A. King, K. Shannon, G. French, and I. Phillips. 1995. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob. Agents Chemother. 39:2478-2483.
32. Stephen, G., and P. D. Jenkins. 1992. Antimicrobial susceptibility tests for β-lactam-β-lactamase inhibitor: predictors of clinical efficacy? Clin. Microbiol. Newsl. 14:89-91.
33. Thomson, C. J., R. S. Miles, and S. G. Amyes. 1995. Susceptibility testing with clavulanic acid: fixed concentration versus fixed ratio. Antimicrob. Agents Chemother. 39:2591-2592.
34. Valdezate, S., J. Martínez-Beltrán, L. de-Rafael, F. Baquero, and R. Cantón. 1996. Beta-lactam stability in frozen microdilution PASCO MIC panels using strains with known resistance mechanisms as biosensors. Diagn. Microbiol. Infect. Dis. 26:53-61.
35. Vanjak, D., C. Mulleys, B. Picard, E. Bergogne-Berezin, and N. Lambert-Zechovsky. 1995. Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents. Eur. J. Clin. Microbiol. Infect. Dis. 14:972-978.
36. Villar, H. E., M. B. Jugo, A. Fernández-Lausi, and A. E. Farinati. 1996. Errores del método de difusión en agar para predecir la susceptibilidad de Escherichia coli frente a ampicilina-sulbactam y amoxicilina-ácido clavulánico. Enferm. Infecc. Microbiol. Clin. 14:308-310.
37. Wiedemann, B., C. Kliebe, and M. Kresken. 1989. Epidemiology of betalactamases. J. Antimicrob. Chemother. 24:1-22.
38. Wu, P. J., K. Shannon, and I. Phillips. 1995. Mechanisms of hyperproduction of TEM-1 β-lactamase by clinical isolates of Escherichia coli. J. Antimicrob. Chemother. 36:927-939.
39. Wu, P.-J., K. Shannon, and I. Phillips. 1994. Effect of hyperproduction of TEM-1 β-lactamase on in vitro susceptibility of Escherichia coli to β-lactam antibiotics. Antimicrob. Agents Chemother. 38:494-498.
40. Zhou, X. Y., F. Bordon, D. Sirot, M.-D. Kitzis, and L. Gutmann. 1994. Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 β-lactamase conferring resistance to β-lactamase inhibitors. Antimicrob. Agents Chemother. 38:1085-1089.